Study Identifies CV Comorbidities Linked to Dermatomyositis Study Identifies CV Comorbidities Linked to Dermatomyositis
The results " represent potential areas for preventative intervention, " the researchers wrote.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 8, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news

This Biomarker Predicts Survival in Autoimmune Lung Disease
(MedPage Today) -- One major subgroup of patients with interstitial lung disease (ILD) arising from polymyositis/dermatomyositis (PM/DM) survived significantly longer when serum levels of interferon-λ3 were relatively low, researchers found... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - December 28, 2023 Category: Rheumatology Source Type: news

Teen With Severe, Recalcitrant Dermatomyositis Seeks New Option
(MedPage Today) -- Treatment-resistant juvenile dermatomyositis resolved by targeting elevated interferon-beta (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - November 24, 2023 Category: Dermatology Source Type: news

IVIG Shows No Impact on VTE Risk in Dermatomyositis Patients IVIG Shows No Impact on VTE Risk in Dermatomyositis Patients
The rate of venous thromboembolism did not increase in dermatomyositis patients treated with intravenous immunoglobulin, compared with those not treated with IVIG.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - May 12, 2023 Category: Dermatology Tags: Rheumatology News Source Type: news

Dermatomyositis: Data Support IFN-Beta as Therapeutic Target Dermatomyositis: Data Support IFN-Beta as Therapeutic Target
Response rates in a phase 2 trial of a novel therapy for skin-predominant dermatomyositis were favorable in patients failed by at least one prior standard therapy, prompting plans for a phase 3 trial.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 21, 2023 Category: Allergy & Immunology Tags: Dermatology News Source Type: news

Trends in Dermatomyositis and Polymyositis Mortality Trends in Dermatomyositis and Polymyositis Mortality
An analysis of mortality data provides insight into the mortality trends for dermatomyositis or polymyositis.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 10, 2023 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Autoantibodies Signal Reduced Cancer Risk in Dermatomyositis Autoantibodies Signal Reduced Cancer Risk in Dermatomyositis
In patients with dermatomyositis positive for anti-TIF1- γ autoantibodies, the presence of anti-CCAR1 autoantibodies indicate normal rather than elevated cancer risk.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 17, 2023 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

Recent Updates: Stroke, Migraine, and Dermatomyositis Recent Updates: Stroke, Migraine, and Dermatomyositis
Hans-Christoph Diener, MD, PhD, discusses recent studies on stroke, migraine, and dermatomyositis.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - December 20, 2022 Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news

Brepocitinib Improves Mild to Moderate AD in Phase 2b Trial Brepocitinib Improves Mild to Moderate AD in Phase 2b Trial
In addition to AD, brepocitinib, a topical TYK2/JAK1 inhibitor, is being developed as a treatment for dermatomyositis, SLE, hidradenitis suppurativa, and non-infectious uveitis.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 29, 2022 Category: Dermatology Tags: Dermatology News Source Type: news

Lenabasum Studied for Refractory Cutaneous Dermatomyositis
TUESDAY, Oct. 11, 2022 -- Lenabasum is well tolerated for the treatment of amyopathic dermatomyositis, according to a phase 2 study published online Oct. 1 in the Journal of Investigative Dermatology. Victoria P. Werth, M.D., from the University of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 11, 2022 Category: Pharmaceuticals Source Type: news

IVIg Proves Effective for Dermatomyositis in Phase 3 Trial IVIg Proves Effective for Dermatomyositis in Phase 3 Trial
Prior to this trial, intravenous immune globulin had not been fully studied for the treatment of dermatomyositis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 7, 2022 Category: Dermatology Tags: Rheumatology News Source Type: news

IV Immune Globulin Bests Placebo for Dermatomyositis
WEDNESDAY, Oct. 5, 2022 -- Significantly more adults with dermatomyositis receiving intravenous immune globulin (IVIG) versus placebo have a response of at least minimal improvement, according to a study published in the Oct. 6 issue of the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 5, 2022 Category: Pharmaceuticals Source Type: news

What Caused This Summer Birthday Party Rash?
Discussion Panniculitides are a diverse group of problems involving inflammation of subcutaneous fat. Subcutaneous fat has limited ability to show different patterns of disease and therefore the clinical appearance is the same but has different etiologies. The skin appears red or purple, swollen, may have discrete nodule(s) or plaque(s) and the affected area can be painful or pruritic. If necessary skin biopsy can help determine the etiology. Overall panniculitides are not very common but some presentations are expected because of particular exposure (i.e. cold) or inflammatory disease processes. Types of panniculitides in...
Source: PediatricEducation.org - August 22, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

What Are Causes of Childhood Interstital Lung Disease?
Discussion Interstitial lung disease in children (chILD) is less understood than adult interstitial lung disease (ILD) and is rare. Prevalence is ~ 0.13 to 16.2 per 100,000 children under age 17 years. chILD is an general term for respiratory disorders that are heterogeneous, chronic and impair lung function. While some define diffuse parenchymal lung disease (DPLD) separately, the term ILD usually encompases DPLD. chILD has variable definitions and is “usually diagnosed if three of the following features are present: 1) respiratory symptoms (cough, rapid and/or difficult breathing, and exercise intolerance), 2) res...
Source: PediatricEducation.org - August 1, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Picture of Dermatomyositis
Title: Picture of DermatomyositisCategory: ImagesCreated: 10/19/2009 12:00:00 AMLast Editorial Review: 6/23/2022 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - June 23, 2022 Category: Dermatology Source Type: news